Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 695-022-6 | CAS number: 473278-76-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 10 - 14 Jan 2005
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 005
- Report date:
- 2005
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- adopted: 29 Jul 2016
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- THE DEPARTMENT OF HEALTH OF THE GOVERNMENT OF THE UNITED KINGDOM
- Type of assay:
- other: in vitro mammalian chromosome aberration test (migrated information)
Test material
- Reference substance name:
- 2-{2-chloro-4-(methylsulfonyl)-3-[(tetrahydrofuran-2-ylmethoxy)methyl]benzoyl}cyclohexane-1,3-dione
- Cas Number:
- 473278-76-1
- Molecular formula:
- C20 H23 Cl O7 S
- IUPAC Name:
- 2-{2-chloro-4-(methylsulfonyl)-3-[(tetrahydrofuran-2-ylmethoxy)methyl]benzoyl}cyclohexane-1,3-dione
Constituent 1
Method
- Target gene:
- not applicable
Species / strain
- Species / strain / cell type:
- mammalian cell line, other: CHL/IU
- Details on mammalian cell type (if applicable):
- CELLS USED
- Source of cells: National Institute of Health Science - Cell Bank
- Doubling time: 17 h
- Number of passages: 6(18) h: P18 -S9, P14 +S9; 24h: P16 -S9
- Methods for maintenance in cell culture if applicable: Cultures were established 16 to 72 hours prior to treatment using the appropriate number of cells per flask depending on the pre-exposure culture period. Cultures were maintained at 37°C in a humidified atmosphere of 5% CO2 in air.
- Modal number of chromosomes: 25
MEDIA USED
- Type and identity of media including CO2 concentration if applicable: Eagle's Minimal Essential Medium (MEM) with HEPES buffer and Earle's Salts supplemented with 10% foetal bovine serum and antibiotics; 5% CO2
- Properly maintained: not specified
- Periodically checked for Mycoplasma contamination: not specified
- Periodically checked for karyotype stability: not specified
- Periodically 'cleansed' against high spontaneous background: not specified - Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- cofactor supplemented post-mitochondrial fraction (S9 mix), prepared from the livers of rats treated with phenobarbital/β-naphthoflavone
- Test concentrations with justification for top dose:
- 6 (18) h exposure: -/+S9: 276.9, 553.8,1107.5, 2215*, 3322.5* and 4430* µg/mL
24 h exposure: -S9: 276.9, 553.8,1107.5, 2215*, 3322.5* and 4430* µg/mL
* selected for metaphase analysis - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: DMSO was selected as the solvent because the test material was readily soluble in it at the required concentrations.
Controls
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- mitomycin C
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in agar (plate incorporation)
- Cell density at seeding: 3x10E04 cells/flask
DURATION
- Exposure duration: 6 h and 24 h
- Expression time (cells in growth medium): 18 h after short term incubation (6h)
- Fixation time (start of exposure up to fixation or harvest of cells): 2 h
SPINDLE INHIBITOR (cytogenetic assays): Colcemid 0.1 µg/mL
STAIN (for cytogenetic assays): Giemsa
METHODS OF SLIDE PREPARATION AND STAINING TECHNIQUE USED: After cells were fixed with glacial acetic acid/methanol (3:1 v/v) solution, several drops of cell suspension were dropped onto clean, wet microscope slides. Slides were dried and stained with Giemsa solution for 5 minutes, rinsed, dried and coverslipped using mounting medium.
NUMBER OF CELLS EVALUATED: 1000
NUMBER OF METAPHASE SPREADS ANALYSED PER DOSE (if in vitro cytogenicity study in mammalian cells): 100 (except where there were approximately 50% of cells with aberrations, then slide evaluation was terminated at 50 cells)
DETERMINATION OF CYTOTOXICITY
- Method: mitotic index, relative total growth
- Any supplementary information relevant to cytotoxicity: A preliminary toxicity test was performed on cell cultures using a 24-hour continuous exposure time without metabolic activation and a 6-h exposure period (both with and without metabolic activation) followed by an 18-h recovery period in treatment-free media. The dose range used was 17.3 to 4430 µg/mL.
OTHER EXAMINATIONS:
- Determination of polyploidy: yes, including endoreduplicated cells if they were not dose related
- Determination of endoreplication: yes
- Evaluation criteria:
- In all circumstances where increases in the frequency of cells with aberrations are seen, statistical comparisons will be made with the vehicle. A positive response was recorded for a particular treatment if the % cells with aberrations, excluding gaps, markedly exceeded that seen in the concurrent control, either with or without a clear dose-relationship. For modest increases in aberration frequency a dose response relationship is generally required and appropriate statistical tests may be applied in order to record a positive response.
- Statistics:
- The frequency of cells with aberrations excluding gaps and the frequency of polyploid cells was compared, where necessary, with the concurrent vehicle control value using Fisher's Exact test.
Results and discussion
Test results
- Key result
- Species / strain:
- mammalian cell line, other: CHL/IU
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- 6 (18h) exposure: 30% growth inhibition at 4430 µg/mL +/-S9; 24 h exposure: 50% growth inhibition at 553.8 and 1107.5 µg/mL
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: at and above 2215 µg/mL
RANGE-FINDING/SCREENING STUDIES: A preliminary cell growth inhibition test was performed at 17.3 to 4430 µg/mL. In all cases the test material showed some evidence of cell toxicity. A precipitate of the test material was seen at and above 2215 µg/mL. Microscopic assessment of the slides prepared from the exposed cultures showed that metaphase cells were present at dose levels up to 4430 µg/mL in the 6 (18)-h without and with S9 exposure groups. The maximum dose with metaphases present in the 24-h continuous exposure group was 2215 µg/mL. The cell growth inhibition data indicated that approximately 50% inhibition was not achieved in the 6 (18)-h exposure group with metabolic activation, or in the 24-hexposure group. In the 6 (18)-h
exposure group without metabolic activation the cell growth inhibition data indicate that 74% inhibition was achieved at the 10 mM limit dose of 4430 µg/mL.
ADDITIONAL INFORMATION ON CYTOTOXICITY:
The dose levels of the test material induced optimum levels of toxicity to CHL cells in the 24-hour continous exposure group, but only modest levels of toxicity in both of the 6 (18)-hour exposure groups at dose levels up to the 10 mM limit dose.
Any other information on results incl. tables
Table 1. Historical control data
solvent control data | ||||||
6 Hour-S9 | 6 Hour+S9 | 24 Hour | ||||
% Cells with Aberrations (- gaps) | % of Polyploid Cells | % Cells with Aberrations (- gaps) | % of Polyploid Cells | % Cells with Aberrations (- gaps) | % of Polyploid Cells | |
Minimum | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum | 4.5 | 1.5 | 3.5 | 1.5 | 3 | 1.5 |
Mean | 1.4 | 0.3 | 0.9 | 0.2 | 1 | 0.4 |
Standard Deviation | 1.2 | 0.4 | 0.8 | 0.4 | 0.8 | 0.4 |
Number of experiments | 28 | 40 | 23 | |||
positive control data | ||||||
6 Hour-S9 | 6 Hour+S9 | 24 Hour | ||||
% Cells with Aberrations (- gaps) | % of Polyploid Cells | % Cells with Aberrations (- gaps) | % of Polyploid Cells | % Cells with Aberrations (- gaps) | % of Polyploid Cells | |
Minimum | 14.5 | 0 | 14 | 0 | 9.7 | 0 |
Maximum | 59 | 2 | 80 | 2.9 | 45 | 1.5 |
Mean | 29.4 | 0.3 | 48.5 | 0.2 | 24.3 | 0.3 |
Standard Deviation | 11.4 | 0.5 | 18.2 | 0.7 | 8.8 | 0.5 |
Number of experiments | 28 | 39 | 22 |
Table 2. Results after 6 (18) h treatment with metabolic activation (+S9)
Number and Percentages of Cells Showing Structural Chromosome Aberrations (%) | Cell Growth Index | Number and Percentages of Cells Showing Numerical Aberrations (%) | |||||||||||||||
Treatment Period (hours) | S9 | Concentration | |||||||||||||||
mix | µg/mL | g | Cell Count % | Mitotic Index (%) | |||||||||||||
Observed | ctb | cte | csb | cse | Others | Total | Observed | Polyploids | Others | Total | |||||||
6(18) | + | Negative Control (DMSO) | A | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 10.7 | 100 | 0 | 0 | 0 |
B | 100 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 100 | 8.2 | 100 | 0 | 0 | 0 | |||
Total | 200 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 9.45 | 200 | 0 | 0 | 0 | ||||
% | 100 | 0 | 0 | 1.0 | 0 | 0 | 1.0 | 0.0 | 100 | 100 | 0 | ||||||
+ | 2215 | A | 100 | 0 | 0 | 0 0 | 0 | 0 | 0 | 84 | 5.3 | 100 | 0 | 0 | 0 | ||
100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71 | 7.6 | 100 | 0 | 0 | 0 | ||||
200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.45 | 200 | 0 | 0 | 0 | |||||
% | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 78 | 68 | 0 | ||||||
+ | 3322.5 | A | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71 | 5.4 | 100 | 0 | 0 | 0 | |
B | 100 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 67 | 8.7 | 100 | 0 | 0 | 0 | |||
Total | 200 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 7.05 | 200 | 0 | 0 | 0 | ||||
% | 100 | 0 | 0 | 0.5 | 0 | 0.0 | 0.5 | 0 | 69 | 75 | 0 | ||||||
+ | 4430 | A | 100 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 56 | 6 | 100 | 0 | 0 | 0 | |
B | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 79 | 8.5 | 100 | 0 | 0 | 0 | |||
Total | 200 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 7.25 | 200 | 0 | 0 | 0 | ||||
% | 100 | 0 | 0 | 0 | 0.5 | 0 | 0.5 | 0 | 68 | 77 | 0 | ||||||
+ | Positive Control (CP) 5 | A | 50a | 6 | 9 | 2 | 2 | 0 | 18 | 7 | 38 | 10.1 | 50 | 0 | 0 | 0 | |
B | 100 | 9 | 14 | 2 | 0 | 0 | 23 | 4 | 39 | 9.3 | 100 | 0 | 0 | 0 | |||
Total | 150 | 15 | 23 | 4 | 2 | 0 | 41*** | 11 | 9.7 | 150 | 0 | 0 | 0 | ||||
% | 100 | 10 | 15.3 | 2.7 | 1.3 | 0 | 27.3 | 7.3 | 39 | 103 | 0 |
DMSO = Dimethylsulphoxide
CP = Cyclophosphamide
*** = p <0.001
a = Slide evaluation terminated at 50 cells because approximately 50% cells with aberrations had been observed
Table 3. Results of 6 (18h) treatment without metabolic activation (-S9)
Number and Percentages of Cells Showing Structural Chromosome Aberrations (%) | Cell Growth lndex | Number and Percentages of Cells Showing Numerical Aberrations (%) | |||||||||||||||||
Treatment Period (hours) | S9 | Concentration | |||||||||||||||||
mix | µg/mL | g | Cell Count% | Mitotic Index(%) | Polyploids | Others | Total | ||||||||||||
24 | Observed | ctb | cte | csb | cse | Others | Total | Observed | |||||||||||
- | Negative Control (DMSO) | A | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 5.8 | 100 | 0 | 0 | 0 | |||
B | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 8.2 | 100 | 0 | 0 | 0 | |||||
Total | 200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 7 | 200 | 0 | 0 | 0 | |||||
% | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 0 | |||||||||
- | 2215 | A | 100 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 75 | 9.2 | 101 | 1 | 0 | 1 | |||
B | 100 | 1 | 0 | 2 | 0 | 0 | 3 | 0 | 73 | 7.8 | 102 | 2 | 0 | 2 | |||||
Total | 200 | 2 | 0 | 3 | 0 | 0 | 5* | 0 | 74 | 8.5 | 203 | 3 | 0 | 3 | |||||
% | 100 | 1 | 0 | 1.5 | 0 | 0 | 2.5 | 0 | 121 | 1.5 | |||||||||
- | 3322.5 | A | 100 | 1 | 1 | 0 | 0 | 0 | 2 | 3 | 66 | 12.2 | 100 | 0 | 0 | 0 | |||
B | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 74 | 6.5 | 100 | 0 | 0 | 0 | |||||
Total | 200 | 1 | 1 | 0 | 0 | 0 | 2 | 4 | 70 | 9.35 | 200 | 0 | 0 | 0 | |||||
% | 100 | 0.5 | 0.5 | 0 | 0 | 0 | 1 | 2 | 134 | 0 | |||||||||
- | 4430 | A | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 65 | 6 | 100 | 0 | 0 | 0 | |||
B | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 75 | 5.9 | 100 | 0 | 0 | 0 | |||||
Total | 200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 70 | 5.95 | 200 | 0 | 0 | 0 | |||||
% | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 85 | 0 | |||||||||
- | Positive Control (MMC) 0.01 | A | 100 | 3 | 28 | 3 | 1 | 0 | 32 | 15 | 59 | 7.6 | 100 | 0 | 0 | 0 | |||
B | 100 | 14 | 14 | 2 | 3 | 0 | 28 | 15 | 63 | 6.4 | 100 | 0 | 0 | 0 | |||||
Total | 200 | 17 | 42 | 5 | 4 | 0 | 60*** | 30 | 61 | 7 | 200 | 0 | 0 | 0 | |||||
% | 100 | 8.5 | 21 | 2.5 | 2 | 0 | 30 | 15 | 100 | 0 |
DMSO=Dimethylsulphoxide
MMC = Mitomycin C
* = p < 0.05
*** =p <0.001
Table 4. Results of 24 h treatment (-S9)
Number and Percentages of Cells Showing Structural Chromosome Aberrations (%) | Cell Growth lndex | Number and Percentages of Cells Showing Numerical Aberrations (%) | |||||||||||||||||
Treatment Period (hours) | S9 | Concentration | |||||||||||||||||
mix | µg/mL | g | Cell Count% | Mitotic Index(%) | Polyploids | Others | Total | ||||||||||||
24 | Observed | ctb | cte | csb | cse | Others | Total | Observed | |||||||||||
- | Negative Control (DMSO) | A | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 3.1 | 100 | 0 | 0 | 0 | |||
B | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 3.9 | 101 | 1 | 0 | 1 | |||||
Total | 200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 3.5 | 201 | 1 | 0 | 1 | |||||
% | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 0.5 | |||||||||
- | 276.9 | A | 100 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 104 | 4.2 | 100 | 0 | 0 | 0 | |||
B | 100 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 98 | 2.7 | 100 | 0 | 0 | 0 | |||||
Total | 200 | 0 | 1 | 0 | 1 | 0 | 2 | 2 | 101 | 3.45 | 200 | 0 | 0 | 0 | |||||
% | 100 | 0 | 0.5 | 0 | 0.5 | 0 | 1 | 1 | 99 | 0 | |||||||||
- | 553.8 | A | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 94 | 1.9 | 100 | 0 | 0 | 0 | |||
B | 94b | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 88 | 1.2 | 94 | 0 | 0 | 0 | |||||
Total | 194 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 91 | 1.55 | 194 | 0 | 0 | 0 | |||||
% | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44 | 0 | |||||||||
- | 1107.5 | A | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 91 | 1.7 | 100 | 0 | 0 | 0 | |||
B | 100 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 74 | 1.7 | 100 | 0 | 0 | 0 | |||||
Total | 200 | 0 | 1 | 0 | I | 0 | 2 | 0 | 83 | 1.7 | 200 | 0 | 0 | 0 | |||||
% | 100 | 0 | 0.5 | 0 | 0.5 | 0 | 1 | 0 | 49 | 0 | |||||||||
- | Positive Control (MMC) 0.05 | A | 50a | 15 | 13 | 2 | 0 | 0 | 25 | 9 | 60 | 5.1 | 50 | 0 | 0 | 0 | |||
B | 50a | 11 | 14 | 0 | 1 | 0 | 24 | 6 | 53 | 3.7 | 50 | 0 | 0 | 0 | |||||
Total | 100 | 26 | 27 | 2 | 1 | 0 | 49*** | 15 | 57 | 4.4 | 100 | 0 | 0 | 0 | |||||
% | 100 | 26 | 27 | 2 | 1 | 0 | 49 | 15 | 126 | 0 |
DMSO = Dimethylsulphoxide
MMC = Mitomycin C
*** = p <0.001
a = Slide evaluation terminated at 50 cells because approximately 50% cells with aberrations had been observed
b = Insufficient metaphases to score 100 cells
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
